Panacea Biotec has received an Award notification from Pan American Health Organization, (PAHO) Regional Office of World Health Organization under a Long-term agreement for supply of Diphtheria-Tetanus-Pertussis-Hepatitis B-Haemophilus influenzae type B (DTP-HepB-Hib) Vaccine (Pentavalent) - Liquid (single dose) (Easyfive-TT) to PAHO, valid until December 31, 2027.
The total award to the company is for supply of Easyfive-TT Vaccine aggregating around $4.75 million (around Rs.41 crore) during Calendar Year 2026 and 2027.
Panacea Biotec is a leading research-based Biotechnology Company with established research, manufacturing and marketing capabilities.
